Issue: February 2021

LinkedIn  Twitter  Vimeo  Facebook
Why You Should Break Up with Your Biobank
The initial excitement and growth of biobanks worldwide has faced several challenges related to logistics, ethics, and utility, 1,2 which call into question the long-term feasibility of a relationship with the traditional biobank. Perhaps it already feels one-sided, transactional, and unbalanced when trying to fulfill the many needs of a research study design. Particularly when trying to obtain broad consent from participants for future research, getting support for a longitudinal study, complex inclusion and exclusion criteria, or fresh sample collection and same-day delivery. So, here’s why we are saying you should break it off.

 

Read more

Precision Medicine for Genetic Disease: from Prevention to Treatment
Jun Liao, Ph.D., FACMG, Laboratory Director and Assistant Professor @Columbia University Medical Center
Sanguine in the news
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, Muik, Derhovanessian et al
Nature (2020)

Read more

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mulligan, Lyke, Kitchin et al
Nature (2020)

Read more

To unsubscribe, click here.

©2022 Sanguine, 318 Bear Hill Road, Suite 1, Waltham, MA 02451 |https://stage.sanguinebio.com/researchers/ | | 818-462-8290